ESTRING (estradiol) by Pfizer is estrogen receptor agonists [moa]. First approved in 1996.
Drug data last refreshed 10h ago · AI intelligence enriched 12h ago
ESTRING is a vaginal estradiol insert delivering localized hormone replacement therapy for moderate-to-severe vasomotor symptoms and vaginal atrophy in postmenopausal women. It works as an estrogen receptor agonist, providing sustained estradiol release directly to vaginal tissue over an extended period. The product represents a targeted, non-systemic approach to menopausal symptom management.
Mature product in LOE phase with stable but modest Medicare utilization; commercial team likely focused on retention and managed decline rather than expansion.
Estrogen Receptor Agonists
Estrogen
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Evaluate the Effect of Vimseltinib on Pharmacokinetics of Combined Oral Contraceptive (Ethinyl Estradiol/Levonorgestrel)
A Trial to Examine the Interaction of Repinatrabit With Ethinyl Estradiol/Norethindrone, Metformin,Carbamazepine, Rosuvastatin, and Methotrexate When Administered Together
A Phase 1 Study to Assess the Effect of ABBV-722 on Ethinyl Estradiol and Levonorgestrel Drug Levels in Healthy Adult Female Participants
Estradiol-mediated Inflammation and Central Sensitization in the Pathophysiology of Endometriosis-associated Pelvic Pain
Drug-drug Interaction Study of Bemnifosbuvir/Ruzasvir (BEM/RZR) and Ethinyl Estradiol/Levonorgestrel (EE/LNG)
Worked on ESTRING at Pfizer? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moUpgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/moESTRING offers limited career growth due to its LOE-approaching status and lack of linked open positions. Roles focused on this product prioritize defending market share and managing decline rather than driving innovation or expansion.